Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
|
|
- Leona Juliet Washington
- 5 years ago
- Views:
Transcription
1 Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K. Silverman, and the COPDGene Investigators. Online Data Supplement
2 Supplement to Methods Section Variable definitions (continued) Pack-years was calculated as the product of the average number of cigarettes smoked per day divided by 20 and multiplied by the number of years smoked. Body mass index was calculated as weight (in kg) divided by height (in meters) squared. Chronic bronchitis was considered present if the subject responded affirmatively to the questions "Do you usually cough like this on most days, for 3 consecutive months or more during the year?" and "Do you usually bring up phlegm on most days for 3 consecutive months or more during the year?" and responded 2 to the questions "How many years have you had this cough?" and "How many years have you had this trouble with phlegm?". Physician diagnosed asthma (ever) was considered present if the patient responded affirmatively to the questions "Have you ever had asthma?" and "Was it diagnosed by a doctor or other health professional?" Current asthma was considered present if, in addition to the two preceeding questions, the subject also responded affirmatively to the question "Do you still have it?" Long acting beta agonist use was considered positive if the subject reported using either a long acting beta agonist or a combination long acting beta agonist and inhaled steroid combination medication. Inhaled corticosteroid use was considered positive if the patient reported a history of inhaled steroid use or combination medication use. Long acting muscarinic antagonist use was considered present if the subject reported tiotropium use. Airway wall measurement technique Using the Pulmonary Workstation Plus package (VIDA Diagnostics, Inc. Coralville, IA), the airway tree was generated using an automated region-growing technique and detailed airway analysis was performed along six selected airway paths (RB1, RB4, RB10, LB1, LB4, and LB10) emcompassing segmental bronchi and two generations of subsegmental bronchi. Emphysema, gas trapping, and wall area measurements were not available in some subjects due to technical limitations.
3 Lower-limit of normal (LLN) defined groups The univariate and multivariate analyses were repeated using the lower limits of normal (LLN)(1) to define COPD, smoking control, and Unclassified groups. Subjects with an FEV1 less than the predicted lower limit of normal and an FEV1/FVC ratio lower limit of normal were considered to have lowerlimit of normal unclassified spirometry (LLN unclassified). Lower limit of normal COPD subjects (LLN-COPD) were defined as subjects with both FEV1/FVC ratio and FEV1 below the LLN. Smoking controls (designated as LLN-controls) had both FEV1/FVC ratio and FEV1 greater than the LLN.
4 References E1. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general u.s. Population. Am J Respir Crit Care Med 1999;159:
5 Supplement to Results Section Supplementary Table E1 Ranges of values for key variables in of LLN -Unclassified subjects Variable Range BMI FEV 1 % predicted % emphysema
6 Supplementary Table E2 - Univariate comparisons between Lower-Limit of Normal Unclassified, Control, and COPD subjects LLN-Unclassified LLN-Controls LLN-COPD N Age 58.8 (8.7) 59.0 (9.4) 63.8 (8.4) * Male (%) Non-white race (%) * Pack-years 47.3 (27) 38.2 (21.4) * 53.5 (26.8)* Current smoking (%) * Heart rate 76.5 (13.3) 74.2 (12.6)* 78.3 (13.1) Body mass index 32.7 (7.2) 28.7 (5.9)* 27.8 (6.1)* 6 minute walk distance(feet) (405.8) (407.1)* 1115 (429.5)* Resting O 2 saturation 96.0 (2.5) 97.0 (1.8) * 94.3 (3.7)* FEV 1 (% predicted) 67.2 (7.5) 96.1 (12.8)* 46.3 (17.1)* FVC (% predicted) 69.8 (8.4) 95.9 (12.7) * 75.0 (17.5)* % emphysema 2.3 (2.7) 3.0 (3.4) * 16.5 (13.5)* % gas trapping 13.9 (9.8) 12.7 (10.1) 44.3 (20.1)* Pi10 ± 3.8 (0.1) 3.7 (0.1) * 3.8 (0.1) Subsegmental wall area % 64.9 (2.3) 63.1 (2.3)* 65.9 (2.4)* Total Lung Capacity (% predicted) 80.6 (13.3) 92.8 (15.3)* (16.8 )* Functional Residual Capacity (% predicted) 87.8 (18.6) 90.5 (20.0) (32.9)* Long acting beta agonist (% of users) * 55.1* Long acting muscarinic antagonist (% of users) * 47.5* Inhaled corticosteroids (% of users) * 57.3* Oral steroids (% of users) * 6.7* St. George's Respiratory Questionnaire 29.3 (22.7) 15.4 (17.1) * 42.0 (20.7)* MMRC 1.5 (1.5) 0.7 (1.1) * 2.3 (1.4) * Chronic cough (%) * 39.1 Chronic sputum (%) * 37.1* Chronic bronchitis (%) * 28.2* Asthma -- Ever (%) * Asthma -- Current (%) * 18* Positive bronchodilator response (%) * History of Congestive Heart Failure (%) * 5.4 Diabetes (%) * 11.9* Hypertension (%) * 47 Stroke (%) TIA (%) Obstructive sleep apnea (%) * 16.5* Data are presented as percent or mean (standard deviation). MMRC = modified Medical Research Council dyspnea score. LLN = Lower Limit of Normal. Bronchodilator response was considered positive if the subject had 0.2L increase in FEV1 or FVC and 12% change in FEV1 or FVC above baseline (pre-bronchodilator) measurements. * denotes p-value <0.05 when compared to GOLD-U subjects For emphysema and TLC, n = 196 (GOLD-U), 1158 (Controls), 939 (COPD) For gas trapping and FRC, n = 176 (GOLD-U), 1055 (Controls), 892 (COPD) ± For Pi10, n= 191 (GOLD-U), 1135 (Controls), 888 (COPD) For subsegmental wall area, n=191 (GOLD-U), 1134 (Controls), 887 (COPD)
7 Supplementary Table E3 Differences by race in LLN-Unclassified subjects White African American N Age 61.5 (8.8) 53 (4.6)* Pack-years 50.9 (28.7) 39.2 (20.7) * BMI 32.2 (6.8) 33.6 (7.8) Current smoking (% of subjects) * FEV1 % predicted 68.2 (7.6) 65.0 (6.9)* FEV/FVC ratio 0.74 (0.06) 0.76 (0.05)* 6MWD (417) 1109 (330.0) * TLC (liters) 5.1 (1.2) 4.2 (1) * % emphysema 2.0 (3) 1.3 (1.3)* % gas trapping 14.5 (9.6) 12.4 (10.3) Subsegmental wall area % 64.5 (2.1) 65.7 (2.6)* Pi (0.10) 3.86 (0.14)* Resting O2 saturation 95.7 (2.6) 96.8 (2.2)* MMRC 1.3 (1.4) 1.8 (1.7) * SGRQ 27.5 (22.1) 33.3 (23.5) Data are presented as mean (SD) or percent. * denotes p-value <0.05 when compared to white subjects.
8 Supplementary Table E4 Prevalence of Restrictive Abnormalities in Lower-Limit of Normal Unclassified, Control, and COPD Subjects LLN-Unclassified LLN- Controls LLN-COPD Total Lung Capacity** (liters) 4.8 (1.2) 5.4 (1.3)* 6.1 (1.5)* Total Lung Capacity % predicted 80.6 (13.3) 92.8 (15.3)* (16.8 )* FVC < 80% predicted (% of subjects) * 61.2* TLC <80% predicted (% of subjects) * 8.0* TLC< LLN (% of subjects) * 6.3* Data are presented as mean (SD) or percent. LLN=lower limit of normal. * denotes p-value <0.05 when compared to GOLD-U subjects. ** based on chest CT measurements
9 Supplementary Table E5 - Multivariable models of Lower Limit of Normal -Unclassified status LLN-Unclassified versus LLN-Controls Clinical variables OR 95% CI Resting O2 saturation [ ] Body mass index [ ] Pack years [ ] 6 minute walk distance (per 100 feet) [ ] Final model includes history of obstructive sleep apnea as a non-significant confounder. Variables tested but not retained in the final model include: chronic bronchitis, physician diagnosed asthma (current), resting heart rate, history of diabetes, congestive heart failure, and hypertension. Clinical + radiographic variables OR 95% CI Diabetes mellitus [ ] Pack-years [ ] Resting O2 saturation [ ] Body mass index [ ] Subsegmental Wall Area % [ ] Additional variables tested but not retained in the final model include: physician diagnosed asthma (current), resting heart rate, six minute walk distance (feet), chronic bronchitis, history of hypertension, congestive heart failure, obstructive sleep apnea, total lung capacity (liters) and % emphysema. LLN-Unclassified vs. LLN-COPD Clinical variables OR 95% CI Age (per 10 years) [ ]* Body mass index [ ] Resting O2 saturation [ ] Bronchodilator response [ ] 6 minute walk distance (per 100 feet) [ ] Asthma (ever) [ ] Current smoking [ ] Diabetes mellitus [ ] Chronic bronchitis [ ] Final model includes pack-years as a non-significant confounder. Additional variables tested but not retained in the final model include: nonwhite race and history of obstructive sleep apnea. * Becomes non-significant following addition of confounder. Clinical + radiographic variables OR 95% CI Bronchodilator response [ ] Resting O2 saturation [ ] Body mass index [ ] % emphysema [ ] % gas trapping [ ] Total lung capacity (liters) [ ] Subsegmental Wall Area % [ ] Final model includes six minute walk distance (feet) as a non significant confounder. Additional variables tested but not retained in the final model include: age, non-white race, current smoking, pack years, chronic bronchitis, history of asthma (ever), diabetes, and obstructive sleep apnea. TLC based on chest CT measurements.
Supplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More information9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUnderstanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationCOPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum
COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationPulmonary Function Testing
In the Clinic Pulmonary Function Testing Hawa Edriss MD, Gilbert Berdine MD The term PFT encompasses three different measures of lung function: spirometry, lung volumes, and diffusion capacity. In this
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 4, Issue 7 Newsletter Date: July 2012 APSR EDUCATION PUBLICATION Inside this issue: Quantitative imaging of airways Small-Airway Obstruction and Emphysema in Chronic Obstructive
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationOccupational exposures are associated with worse morbidity in patients with COPD
Occupational exposures are associated with worse morbidity in patients with COPD Laura M Paulin 1, Gregory B Diette 1,2, Paul D Blanc 3, Nirupama Putcha 1, Mark D Eisner 4, Richard E Kanner 5, Andrew J
More informationQuestion by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)
Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD) A Pulmonary Diagnosis Form is filled out by the reviewer for all medical records that are sent to them for review by the CSCC.
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPersistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction
Persistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction Spyridon Fortis MD, Edward O Corazalla MSc RPFT, David R Jacobs Jr PhD, and Hyun J Kim MD BACKGROUND:
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationPFT Interpretation and Reference Values
PFT Interpretation and Reference Values September 21, 2018 Eric Wong Objectives Understand the components of PFT Interpretation of PFT Clinical Patterns How to choose Reference Values 3 Components Spirometry
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationPulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):
Pulmonary Pearls Christopher H. Fanta, MD Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Medical Pearls Definition: Medical fact that is
More informationVisual Assessment of CT Findings in Smokers With Nonobstructed Spirometric Abnormalities in The COPDGene Study
88 Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research. Visual Assessment of CT Findings in Smokers With Nonobstructed Spirometric Abnormalities in The COPDGene Study
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationThe Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI
The Aging Lung Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI Is the respiratory system of the elderly different when compared to younger age groups? Respiratory Changes
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCOMPARISON OF FEV1 REGARDLESS OF RATIO (FRR) WITH FORCED EXPIRATORY RATIO (FER) IN COPD; TO INCORPORATE PRESERVED RATIO IMPAIRED SPIROMETRY (PRISM)
wjpmr, 2017,3(9), 03-07 SJIF Impact Factor: 4.103 WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH Research Article ISSN 2455-3301 WJPMR COMPARISON OF FEV1 REGARDLESS OF RATIO (FRR) WITH FORCED EXPIRATORY
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationBurden of major Respiratory Diseases
Burden of major Respiratory Diseases WHO Survey Ryazan region of Russia, Ryazan region of Russia, health care system: 104 hospitals district hospitals 32 rural hospitals 44 65 out-patient departments
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD most commonly refers to chronic bronchitis, Mild and Moderate-to-Severe COPD in Nonsmokers* Distinct Demographic Profiles
Mild and Moderate-to-Severe COPD in Nonsmokers* Distinct Demographic Profiles Carolyn E. Behrendt, PhD Study objective: To investigate the risk of COPD among nonsmokers. Design: Case-control study, logistic
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationGOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationSupplementary Online Content
Supplementary Online Content Deslée G, Mal H, Dutau H, et al; REVOLENS Study Group. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical
More informationImpact of the new ATS/ERS pulmonary function test interpretation guidelines
Respiratory Medicine (2007) 101, 2336 2342 Impact of the new ATS/ERS pulmonary function test interpretation guidelines Mary Elizabeth Kreider a,, Michael A. Grippi a,b a Division of Pulmonary, Allergy,
More informationTriennial Pulmonary Workshop 2012
Triennial Pulmonary Workshop 2012 Rod Richie, M.D., DBIM Medical Director Texas Life Insurance Company, Waco, TX EMSI, Waco, TX Lisa Papazian, M.D., DBIM Assistant Vice President and Medical Director Sun
More informationDisclosures. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease May 14, 2016 Orlando, FL COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United States. Alarmingly, COPD recently became
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationAnyone who smokes and/or has shortness of breath and sputum production could have COPD
COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationBusselton is a coastal city in southwestern Western
Obstructive airway disease in 46e65-year-old people in Busselton, Western Australia, 1966e2015 Arthur (Bill) Musk 1, Michael Hunter 2,3, Jennie Hui 2,4, Matthew W Knuiman 2, Mark Divitini 2, John P Beilby
More informationPFTs ACOI Board Review 2018
PFTs ACOI Board Review 2018 Thomas F. Morley, DO, MACOI, FCCP, FAASM Professor of Medicine Chairman Department of Internal Medicine Director of the Division of Pulmonary, Critical Care and Sleep Medicine
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationCoexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis
Volumes: IRV inspiratory reserve volume Vt tidal volume ERV expiratory reserve volume RV residual volume Marcin Grabicki Department of Pulmonology, Allergology and Respiratory Oncology Poznań University
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationLung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationUpdate on Pulmonary Diseases. Jeffrey Lessar, MD
Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationBode index as a predictor of severity in patients with chronic obstructive pulmonary disease.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 5 Ver. VII (May. 2016), PP 93-100 www.iosrjournals.org Bode index as a predictor of severity
More informationabstract n engl j med 374;19 nejm.org May 12,
The new england journal of medicine established in 1812 May 12, 2016 vol. 374 no. 19 Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function Prescott G. Woodruff, M.D., R. Graham
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationBasic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationThe role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE
The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE RHYS JEFFERIES ARTP education Learning Objectives Examine the clinical features of airways disease to distinguish
More informationHEART and LUNG. Heart failure and COPD Χ. ΑΔΑΜΟΠΟΥΛΟΣ ΓΝΘ «ΑΓΙΟΣ ΠΑΥΛΟΣ»
HEART and LUNG Heart failure and COPD Χ. ΑΔΑΜΟΠΟΥΛΟΣ ΓΝΘ «ΑΓΙΟΣ ΠΑΥΛΟΣ» Prevalence of concurrent HF and COPD 8 52 % of HF patients have concurrent COPD More common in male HF patients Prevalence increases
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationCOPD: Applying New Guidelines to Optimizing Evaluation and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information6- Lung Volumes and Pulmonary Function Tests
6- Lung Volumes and Pulmonary Function Tests s (PFTs) are noninvasive diagnostic tests that provide measurable feedback about the function of the lungs. By assessing lung volumes, capacities, rates of
More informationUnderstanding the Basics of Spirometry It s not just about yelling blow
Understanding the Basics of Spirometry It s not just about yelling blow Carl D. Mottram, RRT RPFT FAARC Technical Director - Pulmonary Function Labs and Rehabilitation Associate Professor of Medicine -
More information3 COPD Recognition and Diagnosis: Approach to the Patient with Respiratory Symptoms
William L. Eschenbacher, MD 3 COPD Recognition and Diagnosis: Approach to the Patient with Respiratory Symptoms Key Points 1. Patients who present with respiratory symptoms such as cough, sputum production,
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of insertion of endobronchial nitinol coils to improve lung function in emphysema
More informationCurrent status & future mission for chronic obstrutive airway diseases (COAD) in Asia
Current status & future mission for chronic obstrutive airway diseases (COAD) in Asia Sang-Do Lee, M.D., Ph.D. Division of Pulmonary & Critcal Care Med Asan Medical Center College of Med, Univ. of Ulsan
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationJournal of the COPD Foundation. Journal Club. Chronic Obstructive Pulmonary Diseases:
85 Journal Club Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: inhaled corticosteroid, ICS; long acting β 2 -agonist,
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationGenomewide Linkage of Forced Mid-Expiratory Flow in Chronic Obstructive Pulmonary Disease
ONLINE DATA SUPPLEMENT Genomewide Linkage of Forced Mid-Expiratory Flow in Chronic Obstructive Pulmonary Disease Dawn L. DeMeo, M.D., M.P.H.,Juan C. Celedón, M.D., Dr.P.H., Christoph Lange, John J. Reilly,
More informationPatient reported outcomes in respiratory diseases; How to assess clinical success in COPD
Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Thys van der Molen, University of Groningen, Department of General Practice, The Netherlands Mr Valette Smoking
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationRESPIRATORY PHYSIOLOGY Pre-Lab Guide
RESPIRATORY PHYSIOLOGY Pre-Lab Guide NOTE: A very useful Study Guide! This Pre-lab guide takes you through the important concepts that where discussed in the lab videos. There will be some conceptual questions
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationPULMONARY FUNCTION. VOLUMES AND CAPACITIES
PULMONARY FUNCTION. VOLUMES AND CAPACITIES The volume of air a person inhales (inspires) and exhales (expires) can be measured with a spirometer (spiro = breath, meter = to measure). A bell spirometer
More informationClinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry
BioMed Research International Volume 2013, Article ID 498205, 5 pages http://dx.doi.org/10.1155/2013/498205 Clinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry Jean I. Keddissi,
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationThe Health Impact of Undiagnosed Airflow Obstruction in a National Sample of United States Adults
The Health Impact of Undiagnosed Airflow Obstruction in a National Sample of United States Adults DAVID B. COULTAS, DOUGLAS MAPEL, ROBERT GAGNON, and EVA LYDICK The University of Florida Health Science
More informationInterpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow
REVIEW FEYROUZ AL-ASHKAR, MD Department of General Internal Medicine, The Cleveland Clinic REENA MEHRA, MD Department of Pulmonary and Critical Care Medicine, University Hospitals, Cleveland PETER J. MAZZONE,
More information